At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Suzanne Topalian presented results from an early-stage study showing treatment with the investigational drug BMS-936558.
The drug caused tumour shrinkage in up to a quarter of patients with advanced melanoma, kidney and non-small cell lung (NSCLC) cancers.